Feb 18, 2005
|
Aderis Pharmaceuticals to Participate in Expert Panel on Alzheimer's and Parkinson's Disease at BIO CEO & Investor Conference 2005 |
| |
Dr. William Wheeler will serve as a panelist in a Focus Session titled “Biotech’s Solutions to Alzheimer's and Parkinson's Disease” at BIOCEO conference. |
|
Oct 12, 2004
|
Positive Phase III Trial Results for Rotigotine Patch, Neupro™, in Advanced Parkinson's Disease |
| |
Aderis Pharmaceuticals partner, Schwarz Pharma, announces that Phase III trial with Neupro™ rotigotine transdermal patch in Advanced Parkinson’s disease reports statistically significant and clinically relevant reduction in 'off' time and that 99% of patients continue in the open-label extension trial. |
|
Sep 29, 2004
|
Schwarz Pharma Submits NDA and MAA Applications for Rotigotine Patch Called Neupro™ for the Treatment of Early Parkinson’s Disease |
| |
Aderis Pharmaceuticals partner, Schwarz Pharma, announces that New Drug Application (NDA) and Marketing Authorization Application (MAA) for NeuproTM (rotigotine transdermal system) to treat Parkinson’s disease submitted to the U.S. and the European regulatory authorities for review. |
|
Jul 12, 2004
|
Schwarz Pharma Reports Positive Results for Rotigotine Phase IIb Trials to Treat Restless Legs Syndrome |
| |
Aderis Pharmaceuticals partner, Schwarz Pharma, announces that the multinational Phase IIb trial with rotigotine has shown a statistically significant and clinically relevant reduction of RLS symptoms. |
|
Jun 23, 2004
|
Schwarz Pharma Presents Phase III Data on Rotigotine CDS in Early Parkinson’s Disease |
| |
Aderis Pharmaceuticals partner, Schwarz Pharma, announced that in three consecutive trials rotigotine treatment resulted in clinically relevant superiority over placebo and have shown a significant reduction in symptoms. More than 95% of those completing Phase III trials continued into an open-label extension trial. |
|
Jan 29, 2004
|
King Pharmaceuticals Reports Publication Of Binodenoson Phase II Clinical Data In AHA Journal Circulation |
| |
Aderis’ partner King Pharmaceuticals today reports that the results of Phase II trials of binodenoson, an adenosine A2A receptor agonist for cardiac pharmacologic stress-imaging, are available in the American Heart Association’s journal Circulation |
|
Jan 13, 2004
|
King Pharmaceuticals Completes Initial Dosing in Phase I Trial Involving Treatment for Chronic Diabetic Neuropathic Foot Ulcers |
| |
Aderis Pharmaceuticals’ partner, King Pharmaceuticals, today announced that King’s Phase I trial has completed the initial dosing of MRE0094, a novel adenosine A2A receptor agonist. |
|
Jan 12, 2004
|
Aderis Pharmaceuticals Announces Receipt of $1 Million Milestone Payment for Binodenoson |
| |
King Pharmaceuticals begins Phase III testing of Binodenoson, an adenosine A2A agonist used as a pharmacological stress agent. |
|
Dec 7, 2003
|
King Pharmaceuticals Commences Phase III Clinical Trial Involving Binodenoson |
| |
Aderis Pharmaceuticals’ partner, King Pharmaceuticals, today announced that the Phase III trials of binodenoson, an adenosine A2A receptor agonist for cardiac pharmacologic stress-imaging, have been initiated with the dosing of the first patient. |
|
Nov 10, 2003
|
Aderis Pharmaceuticals Announces The Presentation Of Positive Phase II Selodenoson Atrial Fibrillation Data At American Heart Association (AHA) Scientific Sessions |
| |
Aderis Pharmaceuticals announced today the positive results of a Phase II trial of Aderis Pharmaceuticals’ selodenoson, a selective adenosine A1 agonist being investigated for the control of heart rate in atrial fibrillation. |
|
Oct 27, 2003
|
Schwarz Pharma Announces – Positive Initial Phase III Results for Rotigotine CDS Patch in Two Trials for Parkinson’s Disease in Early Patients |
| |
Comments by Iris Loew-Friedrich of Schwarz Pharma indicate that all primary and secondary endpoints in the two studies were met with statistical significance. |
|
Oct 24, 2003
|
Binodenoson Phase II Clinical Data to be Presented at American Heart Association Scientific Sessions by King Pharmaceuticals |
| |
Results indicate that binodenoson, an adenosine A2A receptor agonist for cardiac pharmacologic stress-imaging, appears to detect myocardial ischemia a well as adenosine, while minimizing side effects like heart block, dyspnea and chest pain. |
|
Sep 4, 2003
|
King Pharmaceuticals Announces – Binodenoson Phase I and II Clinical Trial Results to be Presented at American Society of Nuclear Cardiology Meeting |
| |
Results indicate that binodenoson, an adenosine A2A receptor agonist for cardiac pharmacologic stress-imaging appears to detect myocardial ischemia a well as adenosine, while minimizing side effects like heart block, dyspnea and chest pain. |
|
Aug 20, 2003
|
Aderis Pharmaceuticals’ Phase II Atrial Fibrillation Data Accepted For American Heart Association 2003 Scientific Sessions |
| |
Results of Phase II Trial of Selodenson for the treatment of Atrial Fibrillation presented on November 10, 2003 at 3 PM. |
|
Jun 17, 2003
|
Aderis Pharmaceuticals to Present at BIO 2003 Annual Convention |
| |
Company to Webcast Corporate Presentation and Participate in Panels Discussing Clinical Trials and Private Financing |
|
Apr 28, 2003
|
Aderis Pharmaceuticals To Present At CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference |
| |
Peter Savas, President, CEO and Chairman, to present on Wednesday, April 30, 2003 |
|
Mar 19, 2003
|
Aderis Pharmaceuticals Announces Milestone Payment from Fujisawa Healthcare, Inc. |
| |
Results of Phase II trial of DTI-0009 for treatment of Atrial Fibrillation presented at American Heart Association Meeting |
|
Mar 13, 2003
|
Aderis Pharmaceuticals To Present At Sachs-Bloomberg Global Biotech Investor Forum |
| |
Aderis Pharmaceuticals announced today that President and Chief Executive Officer, Peter Savas, will present a corporate overview on Thursday, March 20 at 3:00 p.m |
|
Feb 19, 2003
|
Aderis Pharmaceuticals to Present at BIO CEO & Investor Conference |
| |
Peter Savas, President, CEO and Chairman, to present on Wednesday, February 26, 2003 |
|
Feb 3, 2003
|
Aderis Pharmaceuticals Named Among Top 15 Biotech Companies of 2003 By FierceBiotech |
| |
Aderis Pharmaceuticals was selected from more than 1,000 privately held biotech companies for their vision, management expertise and overall potential to change how doctors treat disease. |
|
Nov 25, 2002
|
Schwarz Pharma Announces -- Rotigotine CDS Patch: A Novel Transdermal Continuous Delivery System – The Future in Parkinson’s Disease Therapy |
| |
Comments by Professor Rascol of INSERM France, Professor Chase of NIH and Professor LeWitt of the Neuroscience Center in Michigan reflect that a continuous delivery system of dopamine agonist to the brain would benefit Parkinson’s disease patients |
|
Nov 25, 2002
|
Aderis Pharmaceuticals Announces Positive Final Analyses Of Rotigotine CDS Phase II Trial For Restless Legs Syndrome |
| |
Final analyses of Phase II trials indicate that the drug was well tolerated and reduced symptoms at all dose levels. |
|
Oct 10, 2002
|
Schwarz Pharma Announces the Positive Results of Phase II Trial for Rotigotine CDS in Restless Legs Syndrome |
| |
Positive Phase II study shows dose-related reduction of symptoms. Results to be presented at 7th International Congress of Parkinson’s Disease and Movement Disorders in Miami, November 10-14, 2002. |
|
back to top
